Cidara Starts Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Flu

 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced it has reached full planned enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across clinical sites in the US and UK. The trial is designed to evaluate the efficacy and safety of CD388, the company’s DFC for the pre-exposure prophylaxis of seasonal influenza.

https://www.globenewswire.com/news-release/2024/12/04/2991435/0/en/Cidara-Therapeutics-Completes-Enrollment-of-Phase-2b-NAVIGATE-Trial-Evaluating-CD388-for-Prevention-of-Seasonal-Influenza.html